Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | IDH2 | P48735 | 10/20 | 0.60 |
| ▸ | CTSC | P53634 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1391752 | 0.92 | USP2 (0.68) | USP2SMN1; SMN2MAPTIDH2CTSC | |
| SCHEMBL1392745 | 0.92 | MAPT (0.73) | USP2SMN1; SMN2MAPTIDH2LMNA | |
| SCHEMBL1391816 | 0.92 | USP2 (0.58) | USP2SMN1; SMN2MAPTIDH2CTSC | |
| SCHEMBL1392169 | 0.91 | MAPT (0.60) | USP2SMN1; SMN2MAPTIDH2LMNA | |
| SCHEMBL1391823 | 0.91 | IDH2 (0.74) | USP2SMN1; SMN2MAPTIDH2LMNA | |
| SCHEMBL1391661 | 0.91 | IDH2 (0.74) | USP2SMN1; SMN2MAPTIDH2LMNA | |
| SCHEMBL1391666 | 0.89 | SMN1; SMN2 (0.70) | USP2SMN1; SMN2MAPTIDH2LMNA | |
| SCHEMBL1391514 | 0.89 | MAPT (0.57) | USP2SMN1; SMN2MAPTIDH2CTSC | |
| SCHEMBL1391712 | 0.88 | MAPT (0.56) | USP2SMN1; SMN2MAPTIDH2CTSC | |
| SCHEMBL1391595 | 0.88 | MAPT (0.56) | USP2SMN1; SMN2MAPTIDH2CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2231624-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | Progenics Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009091388-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091388-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | HAVCR2, ZC3HAV1, MAVS | USP2 2047/4885SMN1; SMN2 4526/4885MAPT 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.